Guided Psychedelic Therapy: Difference between revisions
mNo edit summary |
mNo edit summary |
||
| Line 13: | Line 13: | ||
=== Digital Evaluative Conditioning === | === Digital Evaluative Conditioning === | ||
There is some evidence to suggest that Guided Psychedelic Therapy can leverage enhanced neuroplasticity to extend the durability of rapid clinical response by employing various digital evaluative conditioning systems. This has been shown in one recent study to triple, – at a minimum the duration of [[Psychedelics|psychedelic]] effect<ref>'''A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion''': A Randomized Clinical Trial Rebecca B. Price, Ph.D., Crystal Spotts, M.Ed., Benjamin Panny, B.S., Angela Griffo, B.S., Michelle Degutis, M.S., Nicolas Cruz, M.Ed., Elizabeth Bell, B.S., Kevin Do-Nguyen, B.S., Meredith L. Wallace, Ph.D., Sanjay J. Mathew, M.D., Robert H. Howland, M.D.https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.20220216</ref>. | There is some evidence to suggest that Guided Psychedelic Therapy can leverage enhanced neuroplasticity to extend the durability of rapid clinical response by employing various digital evaluative conditioning systems. This has been shown in one recent study to triple, – at a minimum the duration of [[Psychedelics|psychedelic]] effect<ref>'''Ongoing clinical trial''' (as of 4th October 2022): [https://clinicaltrials.gov/ct2/show/NCT04578938 Ketamine + Cognitive Training for Suicidality in the Medical Setting]</ref><ref>'''A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion''': A Randomized Clinical Trial Rebecca B. Price, Ph.D., Crystal Spotts, M.Ed., Benjamin Panny, B.S., Angela Griffo, B.S., Michelle Degutis, M.S., Nicolas Cruz, M.Ed., Elizabeth Bell, B.S., Kevin Do-Nguyen, B.S., Meredith L. Wallace, Ph.D., Sanjay J. Mathew, M.D., Robert H. Howland, M.D.https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.20220216</ref>. | ||
'''References''' | '''References''' | ||
Revision as of 10:35, 4 October 2022
The safest way to experience psychedelic therapy is to undergo the experience with a certified guide. Currently, there are very few certified guides due to it being a relatively new area of therapy and varying legality of psychedelics around the globe. However, recently, several training organisations have created new courses offering healthcare practitioners the ability to achieve a Certificate in Psychedelic Assisted Therapy.
According to research trials, the advantages of psychedelics when used in psychotherapy include, but are not limited to, reducing anxiety and depression (including for those who have not found relief from other types of therapy or drug treatment), addressing persistent symptoms of post-traumatic stress disorder, treating addiction, and reducing existential distress in patients with terminal illnesses.
To be a psychedelic guide the following is of the utmost importance:
- Understanding the risk and benefits associated with administering psychedelics.
- Best practice techniques in regards to preparation (before) and integration (after).
- Being up to date with the most recent scientific data.
Digital Evaluative Conditioning
There is some evidence to suggest that Guided Psychedelic Therapy can leverage enhanced neuroplasticity to extend the durability of rapid clinical response by employing various digital evaluative conditioning systems. This has been shown in one recent study to triple, – at a minimum the duration of psychedelic effect[1][2].
References
- ↑ Ongoing clinical trial (as of 4th October 2022): Ketamine + Cognitive Training for Suicidality in the Medical Setting
- ↑ A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial Rebecca B. Price, Ph.D., Crystal Spotts, M.Ed., Benjamin Panny, B.S., Angela Griffo, B.S., Michelle Degutis, M.S., Nicolas Cruz, M.Ed., Elizabeth Bell, B.S., Kevin Do-Nguyen, B.S., Meredith L. Wallace, Ph.D., Sanjay J. Mathew, M.D., Robert H. Howland, M.D.https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.20220216